Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.
Identifieur interne : 001328 ( Ncbi/Merge ); précédent : 001327; suivant : 001329Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.
Auteurs : Mark L. Metersky [États-Unis] ; Robert G. Masterton ; Hartmut Lode ; Thomas M. File ; Timothy BabinchakSource :
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [ 1878-3511 ] ; 2012.
Descripteurs français
- KwdFr :
- Animaux, Antibactériens (usage thérapeutique), Antiviraux (usage thérapeutique), Facteurs de l'âge, Facteurs de risque, Grippe humaine (), Grippe humaine (mortalité), Grippe humaine (traitement médicamenteux), Guides de bonnes pratiques cliniques comme sujet, Humains, Pandémies, Pneumopathie bactérienne (microbiologie), Pneumopathie bactérienne (mortalité), Pneumopathie bactérienne (traitement médicamenteux), Pneumopathie bactérienne (étiologie).
- MESH :
- microbiologie : Pneumopathie bactérienne.
- mortalité : Grippe humaine, Pneumopathie bactérienne.
- traitement médicamenteux : Grippe humaine, Pneumopathie bactérienne.
- usage thérapeutique : Antibactériens, Antiviraux.
- étiologie : Pneumopathie bactérienne.
- Animaux, Facteurs de l'âge, Facteurs de risque, Grippe humaine, Guides de bonnes pratiques cliniques comme sujet, Humains, Pandémies.
English descriptors
- KwdEn :
- Age Factors, Animals, Anti-Bacterial Agents (therapeutic use), Antiviral Agents (therapeutic use), Humans, Influenza, Human (complications), Influenza, Human (drug therapy), Influenza, Human (mortality), Pandemics, Pneumonia, Bacterial (drug therapy), Pneumonia, Bacterial (etiology), Pneumonia, Bacterial (microbiology), Pneumonia, Bacterial (mortality), Practice Guidelines as Topic, Risk Factors.
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Antiviral Agents.
- complications : Influenza, Human.
- drug therapy : Influenza, Human, Pneumonia, Bacterial.
- etiology : Pneumonia, Bacterial.
- microbiology : Pneumonia, Bacterial.
- mortality : Influenza, Human, Pneumonia, Bacterial.
- Age Factors, Animals, Humans, Pandemics, Practice Guidelines as Topic, Risk Factors.
Abstract
Post-influenza bacterial pneumonia is a major cause of morbidity and mortality associated with both seasonal and pandemic influenza virus illness. However, despite much interest in influenza and its complications in recent years, good clinical trial data to inform clinicians in their assessment of treatment options are scant. This paucity of evidence needs to be addressed urgently in order to improve guidance on the management of post-influenza bacterial pneumonia. The objectives of the current article are to evaluate the emergence of the 2009 H1N1 influenza pandemic and use this information as background for an in-depth review of the epidemiology of bacterial pneumonia complicating influenza, to review the bacterial pathogens most likely to be associated with post-influenza bacterial pneumonia, and to discuss treatment considerations in these patients. When determining optimal management approaches, both antiviral and antibacterial agents should be considered, and their selection should be based upon a clear understanding of how their mechanisms of action intervene in the pathogenesis of post-influenza acute bacterial pneumonia.
DOI: 10.1016/j.ijid.2012.01.003
PubMed: 22387143
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D37
- to stream PubMed, to step Curation: 000D37
- to stream PubMed, to step Checkpoint: 000C80
Links to Exploration step
pubmed:22387143Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.</title><author><name sortKey="Metersky, Mark L" sort="Metersky, Mark L" uniqKey="Metersky M" first="Mark L" last="Metersky">Mark L. Metersky</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030-1321, USA. Metersky@nso.uchc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030-1321</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Masterton, Robert G" sort="Masterton, Robert G" uniqKey="Masterton R" first="Robert G" last="Masterton">Robert G. Masterton</name></author><author><name sortKey="Lode, Hartmut" sort="Lode, Hartmut" uniqKey="Lode H" first="Hartmut" last="Lode">Hartmut Lode</name></author><author><name sortKey="File, Thomas M" sort="File, Thomas M" uniqKey="File T" first="Thomas M" last="File">Thomas M. File</name></author><author><name sortKey="Babinchak, Timothy" sort="Babinchak, Timothy" uniqKey="Babinchak T" first="Timothy" last="Babinchak">Timothy Babinchak</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22387143</idno><idno type="pmid">22387143</idno><idno type="doi">10.1016/j.ijid.2012.01.003</idno><idno type="wicri:Area/PubMed/Corpus">000D37</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D37</idno><idno type="wicri:Area/PubMed/Curation">000D37</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D37</idno><idno type="wicri:Area/PubMed/Checkpoint">000C80</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C80</idno><idno type="wicri:Area/Ncbi/Merge">001328</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.</title><author><name sortKey="Metersky, Mark L" sort="Metersky, Mark L" uniqKey="Metersky M" first="Mark L" last="Metersky">Mark L. Metersky</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030-1321, USA. Metersky@nso.uchc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030-1321</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Masterton, Robert G" sort="Masterton, Robert G" uniqKey="Masterton R" first="Robert G" last="Masterton">Robert G. Masterton</name></author><author><name sortKey="Lode, Hartmut" sort="Lode, Hartmut" uniqKey="Lode H" first="Hartmut" last="Lode">Hartmut Lode</name></author><author><name sortKey="File, Thomas M" sort="File, Thomas M" uniqKey="File T" first="Thomas M" last="File">Thomas M. File</name></author><author><name sortKey="Babinchak, Timothy" sort="Babinchak, Timothy" uniqKey="Babinchak T" first="Timothy" last="Babinchak">Timothy Babinchak</name></author></analytic><series><title level="j">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</title><idno type="eISSN">1878-3511</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Animals</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Humans</term><term>Influenza, Human (complications)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (mortality)</term><term>Pandemics</term><term>Pneumonia, Bacterial (drug therapy)</term><term>Pneumonia, Bacterial (etiology)</term><term>Pneumonia, Bacterial (microbiology)</term><term>Pneumonia, Bacterial (mortality)</term><term>Practice Guidelines as Topic</term><term>Risk Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antibactériens (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Facteurs de l'âge</term><term>Facteurs de risque</term><term>Grippe humaine ()</term><term>Grippe humaine (mortalité)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Pandémies</term><term>Pneumopathie bactérienne (microbiologie)</term><term>Pneumopathie bactérienne (mortalité)</term><term>Pneumopathie bactérienne (traitement médicamenteux)</term><term>Pneumopathie bactérienne (étiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Pneumopathie bactérienne</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Grippe humaine</term><term>Pneumopathie bactérienne</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Pneumopathie bactérienne</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Pneumopathie bactérienne</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Animals</term><term>Humans</term><term>Pandemics</term><term>Practice Guidelines as Topic</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Facteurs de l'âge</term><term>Facteurs de risque</term><term>Grippe humaine</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Post-influenza bacterial pneumonia is a major cause of morbidity and mortality associated with both seasonal and pandemic influenza virus illness. However, despite much interest in influenza and its complications in recent years, good clinical trial data to inform clinicians in their assessment of treatment options are scant. This paucity of evidence needs to be addressed urgently in order to improve guidance on the management of post-influenza bacterial pneumonia. The objectives of the current article are to evaluate the emergence of the 2009 H1N1 influenza pandemic and use this information as background for an in-depth review of the epidemiology of bacterial pneumonia complicating influenza, to review the bacterial pathogens most likely to be associated with post-influenza bacterial pneumonia, and to discuss treatment considerations in these patients. When determining optimal management approaches, both antiviral and antibacterial agents should be considered, and their selection should be based upon a clear understanding of how their mechanisms of action intervene in the pathogenesis of post-influenza acute bacterial pneumonia.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22387143</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2012</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int. J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.</ArticleTitle><Pagination><MedlinePgn>e321-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2012.01.003</ELocationID><Abstract><AbstractText>Post-influenza bacterial pneumonia is a major cause of morbidity and mortality associated with both seasonal and pandemic influenza virus illness. However, despite much interest in influenza and its complications in recent years, good clinical trial data to inform clinicians in their assessment of treatment options are scant. This paucity of evidence needs to be addressed urgently in order to improve guidance on the management of post-influenza bacterial pneumonia. The objectives of the current article are to evaluate the emergence of the 2009 H1N1 influenza pandemic and use this information as background for an in-depth review of the epidemiology of bacterial pneumonia complicating influenza, to review the bacterial pathogens most likely to be associated with post-influenza bacterial pneumonia, and to discuss treatment considerations in these patients. When determining optimal management approaches, both antiviral and antibacterial agents should be considered, and their selection should be based upon a clear understanding of how their mechanisms of action intervene in the pathogenesis of post-influenza acute bacterial pneumonia.</AbstractText><CopyrightInformation>Copyright © 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Metersky</LastName><ForeName>Mark L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030-1321, USA. Metersky@nso.uchc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masterton</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Lode</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>File</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Babinchak</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018410" MajorTopicYN="N">Pneumonia, Bacterial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>05</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>01</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22387143</ArticleId><ArticleId IdType="pii">S1201-9712(12)00036-7</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2012.01.003</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Connecticut</li></region></list><tree><noCountry><name sortKey="Babinchak, Timothy" sort="Babinchak, Timothy" uniqKey="Babinchak T" first="Timothy" last="Babinchak">Timothy Babinchak</name><name sortKey="File, Thomas M" sort="File, Thomas M" uniqKey="File T" first="Thomas M" last="File">Thomas M. File</name><name sortKey="Lode, Hartmut" sort="Lode, Hartmut" uniqKey="Lode H" first="Hartmut" last="Lode">Hartmut Lode</name><name sortKey="Masterton, Robert G" sort="Masterton, Robert G" uniqKey="Masterton R" first="Robert G" last="Masterton">Robert G. Masterton</name></noCountry><country name="États-Unis"><region name="Connecticut"><name sortKey="Metersky, Mark L" sort="Metersky, Mark L" uniqKey="Metersky M" first="Mark L" last="Metersky">Mark L. Metersky</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001328 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001328 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:22387143
|texte= Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22387143" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |